Healthcare staffing company AMN Healthcare Services (NYSE: AMN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 99.9% year on year to $1.38 billion. On the other hand, next quarter’s revenue guidance of $627.5 million was less impressive, coming in 1.3% below analysts’ estimates. Its non-GAAP profit of $2.10 per share was 29.9% above analysts’ consensus estimates.

Is now the time to buy AMN Healthcare Services? Find out by accessing our full research report, it’s free.

“Our first quarter performance demonstrated strong execution across AMN, with results exceeding our expectations and guidance while navigating a dynamic market environment,” said Cary Grace, President and Chief Executive Officer of AMN Healthcare.

Company Overview

With a network of thousands of healthcare professionals ranging from nurses to physicians to executives, AMN Healthcare (NYSE: AMN) provides healthcare workforce solutions including temporary staffing, permanent placement, and technology platforms for hospitals and healthcare facilities across the United States.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Regrettably, AMN Healthcare Services’s sales grew at a mediocre 5% compounded annual growth rate over the last five years. This was below our standard for the healthcare sector and is a tough starting point for our analysis.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. AMN Healthcare Services’s recent performance shows its demand has slowed as its revenue was flat over the last two years.

We can better understand the company’s revenue dynamics by analyzing its number of travelers on assignment, which reached 9,227 in the latest quarter. Over the last two years, AMN Healthcare Services’s travelers on assignment averaged 11.5% year-on-year declines. Because this number is lower than its revenue growth, we can see the company benefited from price increases.

This quarter, AMN Healthcare Services reported magnificent year-on-year revenue growth of 99.9%, and its $1.38 billion of revenue beat Wall Street’s estimates by 11.8%. Company management is currently guiding for a 4.7% year-on-year decline in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to decline by 24.2% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and suggests its products and services will see some demand headwinds.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.

AMN Healthcare Services was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 8.7% was weak for a healthcare business.

Analyzing the trend in its profitability, AMN Healthcare Services’s adjusted operating margin decreased by 11.4 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 6.7 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

This quarter, AMN Healthcare Services generated an adjusted operating margin profit margin of 8.5%, up 6.3 percentage points year on year. This increase was a welcome development and shows it was more efficient.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for AMN Healthcare Services, its EPS declined by 7.1% annually over the last five years while its revenue grew by 5%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.

Diving into the nuances of AMN Healthcare Services’s earnings can give us a better understanding of its performance. As we mentioned earlier, AMN Healthcare Services’s adjusted operating margin expanded this quarter but declined by 11.4 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, AMN Healthcare Services reported adjusted EPS of $2.10, up from $0.45 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects AMN Healthcare Services’s full-year EPS of $3.01 to shrink by 78.2%.

Key Takeaways from AMN Healthcare Services’s Q1 Results

It was good to see AMN Healthcare Services beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. On the other hand, its revenue guidance for next quarter slightly missed. Zooming out, we think this was a solid print. The stock traded up 7.4% to $24.13 immediately following the results.

Indeed, AMN Healthcare Services had a rock-solid quarterly earnings result, but is this stock a good investment here? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).